Naoto Inukai
Naoto Inukai has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Akitsu Hotta
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
2 shared publications Hiroyuki Hozumi
T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
2 shared publications- Yukimasa Makita
Takeda-CiRA Joint Program, Fujisawa, Japan
2 shared publications Akihiro Kagita
Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
1 shared publication- Eriya Kenjo
T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
1 shared publication Hidetoshi Sakurai
Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 8 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.
- 8 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Top Cited PapersOpen AccessLow immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.
- Top Cited PapersOpen Access
- 13 March 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.
- 13 March 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-18
Top Cited PapersOpen AccessExtracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping
Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.
- 7 October 2016
- Published by Oxford University Press (OUP) in Microscopy
- Vol. 66 (2) , 136-142
A convenient technique for live-cell observation on the surface of polytetrafluoroethylene with a phase-contrast microscope
Phase-contrast microscopy is a convenient technique for live-cell observation on the surface of materials with high optical transmittance. Here, we demonstrate a novel technique to observe living cells on the surface of materials with low optical transmittance, such as polytetrafluoroethylene (PTFE), which are widely used in biomaterials for blood-contacting devices. The surface of a cover glass was coated with a thin PTFE layer with sufficient transmittance, thereby enabling the observation of living cells on the PTFE surface with a phase-contrast microscope.
- 7 October 2016
- Published by Oxford University Press (OUP) in Microscopy
- Vol. 66 (2) , 136-142
A convenient technique for live-cell observation on the surface of polytetrafluoroethylene with a phase-contrast microscope
Phase-contrast microscopy is a convenient technique for live-cell observation on the surface of materials with high optical transmittance. Here, we demonstrate a novel technique to observe living cells on the surface of materials with low optical transmittance, such as polytetrafluoroethylene (PTFE), which are widely used in biomaterials for blood-contacting devices. The surface of a cover glass was coated with a thin PTFE layer with sufficient transmittance, thereby enabling the observation of living cells on the PTFE surface with a phase-contrast microscope.